Patents Assigned to fx Life Sciences International GmbH
  • Publication number: 20080286389
    Abstract: The invention is directed to chemical processes of preparing fractions form North American ginseng (Panax quinquefolium) and pharmaceutical compositions containing these fractions. The products of the present invention may be used to stimulate the production of cytokines and/or antibodies, or as therapeutics targeted at conditions characterized by low immunity, such as the common cold, influenza, chronic fatigue syndrome, AIDS and cancer.
    Type: Application
    Filed: July 16, 2008
    Publication date: November 20, 2008
    Applicant: fx Life Sciences International GmbH
    Inventors: Jacqueline J. Shan, Peter K.T. Pang, Buhan Huang, Lei Ling
  • Patent number: 7413756
    Abstract: The invention is directed to chemical processes of preparing fractions form North American ginseng (Panax quinquefolium) and pharmaceutical compositions containing these fractions. The products of the present invention may be used to stimulate the production of cytokines and/or antibodies, or as therapeutics targeted at conditions characterized by low immunity, such as the common cold, influenza, chronic fatigue syndrome, AIDS and cancer.
    Type: Grant
    Filed: April 26, 2005
    Date of Patent: August 19, 2008
    Assignee: fX Life Sciences International GmbH
    Inventors: Jacqueline J. Shan, Peter K. T. Pang, Buhan Huang, Lei Ling
  • Patent number: 7358342
    Abstract: A preparation derived from shark cartilage for the treatment of diseases related to excessive PHF or Excessive intracellular calcium.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: April 15, 2008
    Assignee: fX Life Sciences International GmbH
    Inventors: Peter K. T. Pang, Jacqueline J. Shan, Kam Chiu
  • Patent number: 7195783
    Abstract: Hypericin has been shown to specifically inhibited T-type calcium channel activity. Hypericum extract containing hypericin also inhibited T-type calcium channel activity. Moreover, other chemicals in Hypericum extract showed a synergistic effect to hypericin. In view of this, hypericin or hypericin-containing Hypericum extract can be used as T-channel blockers. Hypericum extract, extract of other species of the Hypericum genus, extract of other plants containing hypericin, hypericin, hypericin derivatives, hypericin analogs, such as pseudohypericin, and other hypericum extract constituents can be used as therapeutics targeted at T-type calcium channels for treatment of diseases associated with T-channel abnormality. Methods for administering hypericin and hypericum extract are disclosed.
    Type: Grant
    Filed: January 11, 2000
    Date of Patent: March 27, 2007
    Assignee: FX Life Sciences International GmbH
    Inventors: Jacqueline J. Shan, Xi-Chen Wu, Peter K. T. Pang, Lei Ling
  • Patent number: 7186423
    Abstract: The invention is directed to chemical processes of preparing fractions from North American ginseng (Panax quinquefolium) and pharmaceutical compositions containing these fractions. The products of the present invention may be used to stimulate the production of cytokines and/or antibodies, or as therapeutics targeted at conditions characterized by low immunity, such as the common cold, influenza, chronic fatigue syndrome, AIDS and cancer.
    Type: Grant
    Filed: October 23, 2003
    Date of Patent: March 6, 2007
    Assignee: fx Life Sciences International GmbH
    Inventors: Jacqueline J. Shan, Peter K. T. Pang, Buhan Huang, Lei Ling